OncoCyte Corporation (OCX)
Chart Events
Performance Outlook
| Previous Close | 0.3880 |
| Open | 0.3700 |
| Bid | 0.3753 x 1000 |
| Ask | 0.3890 x 2900 |
| Day's Range | 0.3700 - 0.3890 |
| 52 Week Range | 0.2420 - 1.7500 |
| Volume | |
| Avg. Volume | 394,698 |
| Market Cap | 45.334M |
| Beta (5Y Monthly) | 1.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for OCX
Related Research
- OncoCyte CorporationDaily – Vickers Top Insider Picks for 09/27/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat4 months agoArgus Research
- MarketWatch
Oncocyte cuts 40% of staff
Oncocyte Corp. shares rose 5% in premarket trades after the Irvine, Calif., molecular diagnostics company for the detection of cancer, said it would reduce more than 40% of its workforce "to align its team towards key products that address larger markets." As of Dec. 31, 2021, the company employed full-time 110 people, according to Oncocyte's annual report. The positions of Gisela Paulsen, president and chief operating Officer, and Douglas Ross, chief scientific officer, will be eliminated. Onco
- Simply Wall St.
The past year for OncoCyte (NASDAQ:OCX) investors has not been profitable
Even the best investor on earth makes unsuccessful investments. But serious investors should think long and hard about...
- Simply Wall St.
How Much Of OncoCyte Corporation (NASDAQ:OCX) Do Insiders Own?
The big shareholder groups in OncoCyte Corporation ( NASDAQ:OCX ) have power over the company. Institutions often own...
